ALSTON & BIRD LLP for TRAVERE THERAPEUTICS
What was lobbied
5 issue areas, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
Legislation regarding the Orphan Drug Act and rare disease diagnosis, treatment, and care; H.R. 482/S.350, Newborn Screening Saves Lives Act Reauthorization; H.R. 7506, legislation to revolutionize education, diagnoses, and treatment of rare kidney diseases.
| Lobbyist | Covered position, as disclosed |
|---|---|
| ELINOR HILLER | — |
| JAMES PATRICK PALUSKIEWICZ | — |
| MARK RAYDER | — |
| EMILY A SHAW | — |
| ROBERT SIGGINS | — |
| MARILYN K YAGER | — |
Medicare/Medicaid MMM
H.R. 366, Protecting Access to Post-COVID-19 Telehealth Act and related legislation; H.R. 7506, legislation to revolutionize education, diagnoses, and treatment of rare kidney diseases; H.R. 5376 - Build Back Better Act and Inflation Reduction Act - P.L. 117-169, issues related to Medicare Part B and Part D drug policies and access to therapies for patients with rare diseases.
| Lobbyist | Covered position, as disclosed |
|---|---|
| ELINOR HILLER | — |
| JAMES PATRICK PALUSKIEWICZ | — |
| MARK RAYDER | — |
| EMILY A SHAW | — |
| ROBERT SIGGINS | — |
| MARILYN K YAGER | — |
Pharmacy PHA
Legislation regarding drug pricing, value, and reimbursement; H.R. 3, Elijah Cummings Lower Drug Costs Now Act, and related Senate legislation; H.R. 19, Lower Costs, More Cures Act of 2021; H.R. 5376 - Build Back Better Act and Inflation Reduction Act - P.L. 117-169, issues related to drug policies and access to therapies for patients with rare diseases; H.R. 1629, Fairness in Orphan Drug Exclusivity Act; H.R. 7506, legislation to revolutionize education, diagnoses, and treatment of rare kidney diseases; H.R. 7667, the Food and Drug Amendments of 2022 - provisions concerning accelerated approval, orphan drugs; S. 4348, Food and Drug Administration Safety and Landmark Advancements Act of 2022 - provisions concerning accelerated approval, orphan drugs; H.R. 6963, Accelerated Approval Integrity Act, a bill to amend the Federal Food, Drug, and Cosmetic Act to strengthen requirements for post-approval studies for drugs approved using accelerated approval, and for other purposes.
| Lobbyist | Covered position, as disclosed |
|---|---|
| ELINOR HILLER | — |
| JAMES PATRICK PALUSKIEWICZ | — |
| MARK RAYDER | — |
| EMILY A SHAW | — |
| ROBERT SIGGINS | — |
Medical/Disease Research/Clinical Labs MED
H.R. 7506, legislation to revolutionize education, diagnoses, and treatment of rare kidney diseases; H.R. 1730/S.670, Speeding Therapy Access Today Act; H.R. 7667, the Food and Drug Amendments of 2022 - provisions concerning accelerated approval, orphan drugs; S. 4348, Food and Drug Administration Safety and Landmark Advancements Act of 2022 - provisions concerning accelerated approval, orphan drugs; H.R. 6963, Accelerated Approval Integrity Act, a bill to amend the Federal Food, Drug, and Cosmetic Act to strengthen requirements for post-approval studies for drugs approved using accelerated approval, and for other purposes.
| Lobbyist | Covered position, as disclosed |
|---|---|
| ELINOR HILLER | — |
| JAMES PATRICK PALUSKIEWICZ | — |
| MARK RAYDER | — |
| EMILY A SHAW | — |
| ROBERT SIGGINS | — |
| MARILYN K YAGER | — |
Taxation/Internal Revenue Code TAX
Issues related to Sec. 138141 of H.R.5376, to reduce incentives for clinical testing to develop biopharmaceuticals for individuals suffering from rare/orphan diseases; legislation regarding tax treatment of net operating losses.
| Lobbyist | Covered position, as disclosed |
|---|---|
| MARK RAYDER | — |
| ROBERT SIGGINS | — |
| CAROLYN E SMITH | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.